Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

A Phase 1 Study of FOLR1 CAR T for Pediatric Patients with Relapsed of Refractory AML

FOLR1 CAR T

Condition(s): Myeloid and Monocytic Leukemia
Phase: I
Clinicaltrials.gov ID: NCT06609928

What is the goal of the study?

This phase 1, open-label, non-randomized study will enroll pediatric patients with relapsed or refractory FOLR1+ acute myeloid leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express FOLR1 CAR.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Katherine Tarlock
Study Team Member: HemOnc CRAs, [email protected]

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.